Navigation Links
Green Tea Compound may Be a Therapy for Rheumatoid Arthritis

A new study suggests that a compound in green tea may provide therapeutic benefits to people with rheumatoid arthritis.//

The study, presented at the Experimental Biology 2007 in Washington, looks at a potent anti-inflammatory compound derived from green tea. Researchers found that the compound -- called epigallocatechin-3-gallate (EGCG) -- inhibited the production of several molecules in the immune system that contribute to inflammation and joint damage in people with rheumatoid arthritis.

The compound from green tea also was found to suppress the inflammatory products in the connective tissue of people with rheumatoid arthritis.

"Our research is a very promising step in the search for therapies for the joint destruction experienced by people who have rheumatoid arthritis," says Salah-uddin Ahmed, Ph.D., lead researcher on the study. Ahmed, a research investigator with the Division of Rheumatology at the U-M Health System, was selected to present the research at the Experimental Biology meeting as the recipient of the Young Scientist Travel Award, given by the American Society for Pharmacology and Experimental Therapeutics. This study was also selected by the American Society for Nutrition to be featured in a press release.

To conduct the research, the scientists isolated cells called synovial fibroblasts from the joints of patients with rheumatoid arthritis. These fibroblasts -- cells that form a lining of the tissue surrounding the capsule of the joints -- then were cultured in a growth medium and incubated with the green tea compound.

The fibroblasts were then stimulated with pro-inflammatory cytokine IL-1?ò, a protein of the immune system known to play an important role in causing joint destruction in people with rheumatoid arthritis.

The researchers looked at whether the green tea compound has the capability to block the activity of two potent molecules, IL-6 and cyclooxygenase-2 (COX-2
'"/>




Page: 1 2

Related medicine news :

1. Green tea beneficial in preventing osteoarthritis
2. Eating Greens fights cancer
3. Green Onions Blamed in Outbreak
4. Green Tea Might Help Patients With Prostate Cancer
5. Yet Another Use For Green Tea Extract
6. Exposure To Greenery And Graffiti May Affect Obesity
7. Green Beans for Cancer Prevention and Treatment.
8. Can Green Tea Prevent Alzheimers?
9. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients
10. Polyphenols in Green Tea Cause Liver Damage At High Doses
11. FDA Gives Green Signal To Sanofi-Aventis SAs Cancer Drug Taxotere
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...scinating areas of biology today, with new experim...about the potential applications of stem cells. Sc...rat // sperm cells to behave like embryonic stem c... to various cell lineages such as a nerve cell, bl...
...ence Livermore National Laboratory are studying th...derstand the mechanism of protein folding. The new...// how a protein is incorrectly folded which leads...ublished in the Journal Proceedings of the Nationa...
...'ll see that lots of middle-aged men are losing th...a bit, it turns out, reports AP. A British compan...und with hundreds more hairs than they had before,...n called hair cloning. An American outfit hopes to...
...the AIDS epidemic, South Africa's first Phase II H...p the International AIDS Vaccine Initiative (IAVI)... The trials will test the safety of "tgAAC09" is a... is based on HIV subtype C, the subtype of the vir...
Other Medicine News:Health News:Sperm stem cells could be an alternative to embryonic stem cells in future 2Health News:Scientists Seek New Ways To Grow Hair On Bald Pates 2Health News:Scientists Seek New Ways To Grow Hair On Bald Pates 3Health News:Scientists Seek New Ways To Grow Hair On Bald Pates 4Health News:Phase II trails of new HIV vaccine to be held in South Africa 2
(Date:9/3/2008)...G, Md., Sept. 3 /- Panacea Pharmaceut...atent Number 7,413,737 covering,antibodies against...AH), a,proprietary human cancer biomarker and ther... collaboration with the Massachusetts Institute of...wide rights to this patent,for development of huma...
(Date:9/3/2008)... Trial Reconfirms Strong Evidence Pycnogenol(R) Lo...ffect on Joints Following Cessation .... 3 /- According to the Center for,Di...on type of arthritis,is on the rise. A new study ...search, reveals Pycnogenol(R), bark extract from t...
(Date:9/2/2008)...ember 3 /-, - This Analysi...e Risk,of Stroke by 34% in Patients With Atrial Fi...eated by Antithrombotic Therapy, The results of a...dy,were presented today at the clinical trial upda...ongress 2008, in Munich, Germany. Previous results...
(Date:9/2/2008)...y Meets Primary Bone Mineral Density and Secondary... Company to Host Conference Call and Webcast Wedn...0 am ET / 5:30 am PT, SAN DIEGO, Sept. 2 /PRNewsw...sdaq: NBIX ) today announced positive safety and ...trial using its proprietary, orally-active,nonpept...
Breaking Medicine Technology:Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 2Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 3Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 4Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 5Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 6Reflecting on the social implications of human genetics research past present and future 2780 1Reflecting on the social implications of human genetics research past present and future 2780 2Analysis Highlights Economic Contribution of Hospitals to Communities 16090 1Analysis Highlights Economic Contribution of Hospitals to Communities 16090 2Quest Diagnostics to Release First Quarter 2008 Financial Results and Conduct Quarterly Investor Conference Call 16088 1Quest Diagnostics to Release First Quarter 2008 Financial Results and Conduct Quarterly Investor Conference Call 16088 2VA Announces SGLI and VGLI Premium Reductions 16086 1VA Announces SGLI and VGLI Premium Reductions 16086 2
...nistration show potential for,new option to improv...07 /PRNewswire-FirstCall/ -- Millennium,Pharmaceut...sitive,data for VELCADE, the market-leading therap... received at least one prior therapy.,These data i...ous,(SC) administration of VELCADE, a new option u...
...llicular Lymphoma Reported,Today at ASCO Annual Me... GlaxoSmithKline plc,announced today long-term eff...eek course of frontline treatment with the BEXXAR(...31 Tositumomab) in,76 patients with newly diagnose.... This regimen was found to induce durable clinica...
Other Medicine Technology:New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 2New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 3New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 5New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 6New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 78-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
Medicine Products: